DNB Fund - Low Volatility Equities Retail A (N) (NOK)

Equity fund

1 year

Globe

USA

Largest region

Medium

Risk

Annual costs

Morningstar

 

Partial 

Sustainability

Development

Last 5 years
( ann.)

Description

  • DNB Low Volatility Equities N er en nettoandelsklasse hvor de årlige kostnadene blir lavere. Fondet har som mål å oppnå, med minimal eksponering for volatilitet, en positiv relativ avkastning på lang sikt. Fondet investerer hovedsakelig i aksjer i selskaper som viser relativt lav volatilitet og konsentrasjonsrisiko. Geografisk har underfondet full fleksibilitet. Fondets basisvaluta er EUR. Fondet følger en aktivt forvaltet strategi. Referansegrunnlaget er MSCI World Index. Fondet belaster ikke suksesshonorar

Investment horizon

  • DNB Fund - Low Volatility Equities Retail A (N) (NOK) is a Equity fund. This mutual fund type is suitable for those who plan to save for at least 6 years.

Characteristics

  • Minimum amount
  • Sharpe 3 years
  • Price/NAV

    04 Sept 2025

  • Start date
    18 Dec 2019
  • ISIN
    LU2075956321

Risk

  • Medium (4 of 7)

Morningstar rating

  • The Morningstar Rating is an objective standard that tells us how well a fund has done compared to similar funds. If a fund performs better than other funds it is compared with, it receives a high rating. Correspondingly, a fund receives a low rating if it performs worse than similar funds.

Sustainability

Annual cost

  • Ongoing costs

    Includes management fees of 0,60 %

  • Platform fee
  • Kickback fee
  • Annual running costs

Other costs

  • Performance-based fee
  • Transaction costs
  • Costs for any currency exchanges are not included.

Allocation

  • Stocks 99%
    Interest 1%

Portfolio

Shows the fund's largest investments.

  • Microsoft Corp
    4.4%
  • NVIDIA Corp
    3.6%
  • Apple Inc
    3.0%
  • Johnson & Johnson
    2.7%
  • Cisco Systems Inc
    2.4%
  • Verizon Communications Inc
    2.3%
  • HSBC Holdings PLC
    2.3%
  • CME Group Inc Class A
    2.2%
  • Waste Connections Inc
    2.2%
  • Merck & Co Inc
    2.2%